Canadian CANNAINVESTOR Magazine August / September 2017 - Page 136


Other methods such as those mentioned earlier on that have either been released, or are in development, could be a more viable option for seniors, and as the survey states, 14% choose edibles, and a whopping 38% choose something else entirely from traditional forms of delivery. For example, according to the International Journal of Pharmacy and Life Sciences, the oral transmucosal route is gaining importance for systemic drug delivery because it does have significant advantages compared to the per oral route. The oral spray technology offers formulation of many pharmacological

agents making it preferred mode of delivery in diseases like angina, diabetes, and cardiovascular diseases. It allows more rapid absorption into the bloodstream than is possible with oral administration to the gastrointestinal tract. Oral spray administration is non-invasive, non-technical and convenient for patients. LP’s such as Hydropothecary have recently introduced a spray to appeal to those that may require this type of method, or prefer it. Its Elixir No.1 peppermint medical cannabis oil sublingual mist is high in THC (up to 30 mg/ml, which is the maximum according to the ACMPR) and is discreet and convenient, which can appeal to all cannabis users, but seems to fit into the preferences in these two demographic market segments.

Back in February, CanniMed Therapeutics Inc. (TSX:CMED) announced that it entered into a contractual relationship with CTT Pharmaceutical Holdings Inc. (OTC:CTTH) for the licensing of CTT’s Orally Dissolvable Thin Film Wafer

technology, broadening its ability to provide patients with stand-ardized, dose-sensitive and discrete delivery systems. These wafers are suitable for geriatric and pediatric patients that have difficulty swallowing or those suffering from Phagophobia (fear of swallowing) or Pnigophobia (fear of choking).